Secord AA, et al. - In this phase II study, researchers examined the antitumor activity of nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors, in bevacizumab-resistant recurrent epithelial ovarian cancer (EOC), tubal, and peritoneal cancer. Nintedanib 200 mg/day was evaluated in 27 patients evaluable for PFS; 26 evaluable for 6-month progression-free survival (PFS6m). In an unselected bevacizumab-resistant EOC population, they observed the minimal activity of single-agent nintedanib. Patients tolerated nintedanib with manageable toxicities. Prognostic markers for progressive disease included plasma CD73, IL6, and VEGFD, and worse PFS was observed in correlation with IL6. Patients treated with other anti-angiogenic agents showed similar observations confirming the findings.